



Return on Investment in Needle and Syringe Programs in Australia

Report

Return on Investment in Needle and Syringe Programs in Australia • Report



**COMMONWEALTH DEPARTMENT OF
HEALTH AND AGEING**

RETURN ON INVESTMENT IN NEEDLE &
SYRINGE PROGRAMS IN AUSTRALIA

REPORT

HEALTH OUTCOMES INTERNATIONAL PTY LTD

IN ASSOCIATION WITH

THE NATIONAL CENTRE FOR HIV EPIDEMIOLOGY AND
CLINICAL RESEARCH

AND

PROFESSOR MICHAEL DRUMMOND, CENTRE OF HEALTH
ECONOMICS, YORK UNIVERSITY

© Commonwealth of Australia 2002

ISBN 0 642 82116 X

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth available from the Department of Communications, Information Technology and the Arts. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Copyright Services, Info Access, GPO Box 1920, Canberra ACT 2601.

Publication approval number: 3122

Publications Production Unit (Public Affairs, Parliamentary and Access Branch)
Commonwealth Department of Health and Ageing

EXECUTIVE SUMMARY	1
EFFECTIVENESS OF NSPs FOR PREVENTING TRANSMISSION OF HIV AND HCV INFECTION	1
FINANCIAL EFFECTS OF NSPs	2
QUALITY OF LIFE (QoL) EFFECTS OF NSPs	4
CONCLUSION	6
1 INTRODUCTION	7
1.1 BACKGROUND	7
1.2 OBJECTIVES	7
1.3 METHODOLOGY.....	8
1.4 ACKNOWLEDGEMENT	8
2 AN OVERVIEW OF NEEDLE AND SYRINGE PROGRAMS (NSPs)	9
2.1 AUSTRALIA'S STRATEGIES ON HIV/AIDS AND HEPATITIS C.....	9
2.2 OVERVIEW OF NEEDLE AND SYRINGE PROGRAMS	9
2.3 OPERATIONS OF NEEDLE AND SYRINGE PROGRAMS.....	10
3 THE IMPACT OF NSPs ON HIV AND HCV	12
3.1 EFFECTIVENESS OF NSPs FOR PREVENTING TRANSMISSION OF HIV AND HCV INFECTION	12
3.2 METHODOLOGY FOR ESTIMATES OF NUMBERS OF PEOPLE LIVING WITH HIV ACQUIRED THROUGH INJECTING DRUGS.....	25
3.3 METHODOLOGY FOR ESTIMATES OF NUMBERS OF PEOPLE LIVING WITH HCV ACQUIRED THROUGH INJECTING DRUGS.....	27
3.4 NUMBER OF HIV INFECTIONS PREVENTED THROUGH THE INTRODUCTION OF NSPs.....	29
3.5 NUMBER OF HCV INFECTIONS PREVENTED THROUGH THE INTRODUCTION OF NSPs	30
4 FINANCIAL EFFECTS OF NSPs	31
4.1 DESCRIPTION OF THE ECONOMIC MODEL.....	31
4.2 EXPENDITURE ON NSPs.....	32
4.3 IMPACTS OF NSPs ON HIV AND HCV	33
4.4 METHODOLOGY FOR HEALTH CARE COSTINGS FOR HIV	36
4.5 METHODOLOGY FOR HEALTH CARE COSTINGS FOR HCV INFECTION	38
4.6 HIV TREATMENT COSTS	39
4.7 RETURN ON INVESTMENT.....	42
4.8 SENSITIVITY ANALYSIS.....	44
4.9 DISCUSSION.....	45
5 QUALITY OF LIFE (QoL) EFFECTS OF NSPs	47
5.1 INTRODUCTION.....	47
5.2 QUALITY-ADJUSTED LIFE-YEARS (QALYs).....	48

5.3	METHODOLOGY FOR ESTIMATING THE QALYS GAINED FROM THE PREVENTION OF HIV AND HCV INFECTIONS.....	48
5.4	NUMBER OF CASES OF HIV AND HCV AVOIDED	50
5.5	NUMBER OF LIFE YEARS GAINED	50
5.6	QUALITY ADJUSTED LIFE YEARS GAINED	52
5.7	SENSITIVITY ANALYSIS.....	55
5.8	DISCUSSION.....	56
APPENDICES		
APPENDIX A	OVERVIEW OF STATE AND TERRITORY NEEDLE AND SYRINGE PROGRAMS	57
APPENDIX B	DISCUSSION OF THE METHODOLOGY USED IN THE ECOLOGICAL STUDY	73
APPENDIX C	DETAILED TABLES OF EFFECTS OF NSPs ON HIV AND HCV.....	75
APPENDIX D	DETAILED TABLES ON FINANCIAL EFFECTS AND NPV OF NSPs	105
APPENDIX E	DETAILED TABLES ON QUALITY OF LIFE EFFECTS OF NSPs	125
APPENDIX F	REFERENCES.....	145